Admedus' CardioCell biomaterial scaffold technology validated by independent peer-reviewed study

Admedus Ltd (ASX:AHZ) has had its CardioCel transcatheter aortic valve replacement (TAVR) devices validated through the publication of an independent study assessing the technology's performance in peer-reviewed journal The Annals of Thoracic Surgery.

The article, "Multi-centre experience with 500 CardioCel implants used for the repair of congenital heart defects", delivers the positive finding that CardioCel has good durability in paediatric patients.

It also shows that CardioCel performs comparably on the systemic and pulmonary circulations with no evidence of patch calcification, with 96% of patients free from reintervention at three and five years.

Admedus chief medical officer Dr Kiran Bhirangi said the results of the study were overwhelmingly positive for the medical technology company.

He said that it reinforces the evidence that ADAPT biomaterial scaffold tissue has superior durability.

Bhirangi added: "It demonstrates, across a large patient population presenting with a range of disease types, that CardioCel provides a solution with few complications and minimal chance of required intervention."

“This is particularly relevant for paediatric patients who need to lead healthy and active lives, without the need for ongoing surgery.”

READ: Admedus divests Infusion business for $6.3 milion in restructure based on ADAPT portfolio growth strategy

The primary endpoint of the study was freedom from trans-catheter or surgical implant-related reintervention.

Secondary endpoints included interoperative and perioperative mortality, calcification, infection and thrombosis.

These secondary endpoints demonstrated an excellent safety and durability profile, with one case of thrombosis and one case of patch dehiscence (separation) recorded across the entire patient population.

The article also discussed the cost-benefit analysis of CardioCel, highlighting it as a cost-effective solution compared with other bioscaffolds, due to the reduced need for repeat surgery and improved quality of life.

READ: Admedus divesting non-core business to focus on ADAPT product portfolio

Admedus chief executive officer Wayne Paterson said the study reinforced the clinical superiority of CardioCel, which used the company's proprietary ADAPT tissue.
He added: “This large body of independent data, published in a highly respected peer-review journal, is a very important milestone.

“The data will support further market adoption not only for CardioCel but our entire ADAPT portfolio.

“It also reinforces the clinical and commercial potential of our 3D single piece aortic valve and TAVR devices in development.

“Each will have the same anti-calcification properties, key differentiators and improvement on existing solutions.

“We are now rapidly progressing towards first-in-human studies and look forward to providing an update in due course.”

READ: Admedus to spin-off immunotherapies business; shares surge
CardioCel performance was consistent across the three patient groups which were: babies 28 days and younger, infants aged from one month to one year and children older than one year.

The study collected data over five years across 377 patients in Brisbane and two UK sites, Bristol and Leicester.

It is the largest series of data collected on the use of CardioCel in humans.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars ($25,000).